SCHEMBL30656804

SCHEMBL30656804

Nc1ccc2ncn(CCN3CCCCC3)c(=O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.53
KDM4E B2RXH2 5/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 4/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 4/20 0.45
HPGD P15428 3/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
RCE1 Q9Y256 1/20 0.45
ACVR1 Q04771 1/20 0.44
P2RX3 P56373 3/20 0.44
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
MMP13 P45452 1/20 0.43
DRD2 P14416 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24166800 1.00 TNF (0.53) TNFKDM4ETP53POLBHSD17B10
SCHEMBL30656805 0.89 ACVR1 (0.56) TNFKDM4EHSD17B10HTTTDP1
SCHEMBL24166881 0.89 ACVR1 (0.56) TNFKDM4EHSD17B10HTTTDP1
SCHEMBL29724004 0.85 MCL1 (0.50) KDM4ETP53POLBHSD17B10TSHR
SCHEMBL29724027 0.84 AURKA (0.49) KDM4ETP53POLBHSD17B10TSHR
SCHEMBL30656798 0.83 ACVR1 (0.64) TNFKDM4EHSD17B10HTTALDH1A1
SCHEMBL24166797 0.83 ACVR1 (0.64) TNFKDM4EHSD17B10HTTALDH1A1
SCHEMBL6143710 0.81 DRD2 (0.62) KDM4ETP53POLBTDP1DRD2
SCHEMBL30656794 0.81 L3MBTL1 (0.58) KDM4ETP53POLBHSD17B10TSHR
SCHEMBL26758096 0.81 L3MBTL1 (0.58) KDM4ETP53POLBHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC TNF 4408/4885KDM4E 1291/4885TP53 3874/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 TNF 4482/4885KDM4E 402/4885TP53 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.